Teneurin C-terminal associated peptide (TCAP)-1 attenuates the development and expression of naloxone-precipitated morphine withdrawal in male Swiss Webster mice
Psychopharmacology · 2024
DOI: 10.1007/s00213-024-06582-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmacology, 2024. Verfasst von Lauren E Mueller und 4 weiteren Autor:innen. Beteiligte Einrichtung: Protagenic Therapeutics, Inc., New York, NY, USA. Hauptthemen laut MEDLINE: Substance Withdrawal Syndrome, Naloxone, Narcotic Antagonists, Morphine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rationale
Corticotropin-releasing factor (CRF), the apical stress-inducing hormone, exacerbates stress and addictive behaviors. TCAP-1 is a peptide that directly inhibits both CRF-mediated stress and addiction-related behaviors; however, the direct action of TCAP-1 on morphine withdrawal-associated behaviors has not previously been examined.
Objective
To determine whether TCAP-1 administration attenuates behavioral and physiological consequences of morphine withdrawal in mice.
Methods
Mice were administered via subcutaneous route TCAP-1 either before or after initial morphine exposure, after which jumping behavior was quantified to assess the effects of TCAP-1 on naloxone-precipitated morphine withdrawal. As a comparison, mice were treated with nonpeptide CRF 1 receptor antagonist CP-154,526. In one experiment, plasma corticosterone (CORT) was also measured as a physiological stress indicator.
Results
Pretreatment with TCAP-1 (10–250 nmol/kg) before morphine treatment significantly inhibited the development of naloxone-precipitated withdrawal. TCAP-1 (250–500 nmol/kg) treatment administered after morphine treatment attenuated the behavioral expression of naloxone-precipitated withdrawal. TCAP-1 (250 nmol/kg) treatment during morphine treatment was more effective than the optimal dosing of CP-154,526 (20 mg/kg) at suppressing the behavioral expression of naloxone-precipitated withdrawal, despite similar reduction of withdrawal-induced plasma CORT level increases.
Conclusions
These findings establish TCAP-1 as a potential therapeutic candidate for the prevention and treatment of morphine withdrawal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Protagenic Therapeutics, Inc., New York, NY, USA.
- NeoSome Life Sciences, Lexington, MA, USA.
- Department of Cell and Systems Biology, University of Toronto, Toronto, CA, Canada.
- Protagenic Therapeutics, Inc., New York, NY, USA. Andrew.Slee@Protagenic.com.
Zitieren
APA
Mueller, L. E., Wexler, R. S., Lovejoy, D. A., Stein, R. B., & Slee, A. M. (2024). Teneurin C-terminal associated peptide (TCAP)-1 attenuates the development and expression of naloxone-precipitated morphine withdrawal in male Swiss Webster mice. Psychopharmacology. https://doi.org/10.1007/s00213-024-06582-0
Vancouver
Mueller LE, Wexler RS, Lovejoy DA, Stein RB, Slee AM. Teneurin C-terminal associated peptide (TCAP)-1 attenuates the development and expression of naloxone-precipitated morphine withdrawal in male Swiss Webster mice. Psychopharmacology. 2024. doi:10.1007/s00213-024-06582-0
BibTeX
@article{Mueller2024,
author = {Mueller, Lauren E and Wexler, Roseanne S and Lovejoy, David A and Stein, Robert B and Slee, Andrew M},
title = {Teneurin C-terminal associated peptide (TCAP)-1 attenuates the development and expression of naloxone-precipitated morphine withdrawal in male Swiss Webster mice},
journal = {Psychopharmacology},
year = {2024},
doi = {10.1007/s00213-024-06582-0}
}
EUVIMED